

## Developing next generation therapies for autoimmune diseases

Founded in 2002 by Dr. Robert Huber (Chemistry Nobel Laureate 1988), Dr. Uwe Jacob and Dr. Peter Sondermann, SuppreMol uses its expertise in purification, crystallization, and x-ray diffraction analysis of Fc-receptors to develop next generation therapies for autoimmune diseases. Its lead program, SM101, is a soluble human Fc-receptor which binds to immune complexes and down regulates inflammation, cellular immune response, and B-cell activation. This novel approach could lead to potentially curing disorders vs. merely treating symptoms.

### Lead program SM101 (Fc $\gamma$ RIIb)


**Non-glycosylated Form of Fc-receptor:** a naturally occurring protein in human blood produced by recombinant technology in *E. coli*

**Mechanism of Action:** Binds to auto-antibody/auto-antigen complexes thereby blocking the uptake of these complexes by immune cells. Feedback regulation will lead to down regulation of the immune response by reducing/removing specific B-cells responsible for production of autoimmune antibodies. Non-target B-cells (ie, participating in regular immune reactions) are not affected, hence reducing possible side-effects such as increased susceptibility to infections.

**Validation in Collagen Mouse Model:** Strong efficacy in the later, relevant stage of autoimmune disease = decrease in inflammation and immune reaction.

**Potential Markets:** Idiopathic Thrombocytopenic Purpura (ITP), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), etc.

### Preparing IND filing: anticipate start of Phase I in Q4 2008



### The plan moving forward: complete series B

The Company is seeking to raise 10-12 million (EUR) via its series B round to initiate a phase I trial for ITP in single dose escalation studies, phase Ib/IIa efficacy studies, and facilitate corporate growth. The round will provide funding through Q4 2010.

CONTACT:

Peter Buckel, CEO  
buckel@suppremol.com